Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression
{{output}}
Resectable locally advanced EGFR-mutant non-small cell lung cancer (NSCLC) represents a distinct therapeutic challenge. Owing to an inherently immunosuppressive tumor microenvironment-frequently characterized by absence of or low PD-L1 expression and sparse CD... ...
